| The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti‐tumour necrosis factor H Alric, A Amiot, J Kirchgesner, X Tréton, M Allez, Y Bouhnik, L Beaugerie, ... Alimentary pharmacology & therapeutics 51 (10), 948-957, 2020 | 117 | 2020 |
| Effectiveness and safety of reference infliximab and biosimilar in Crohn disease: a French equivalence study A Meyer, J Rudant, J Drouin, A Weill, F Carbonnel, J Coste Annals of Internal Medicine 170 (2), 99-107, 2019 | 117 | 2019 |
| Systematic review with meta‐analysis: comparative risk of lymphoma with anti‐tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease A Chupin, V Perduca, A Meyer, C Bellanger, F Carbonnel, C Dong Alimentary Pharmacology & Therapeutics 52 (8), 1289-1297, 2020 | 89 | 2020 |
| Food processing and risk of inflammatory bowel disease: a systematic review and meta-analysis N Narula, NH Chang, D Mohammad, ECL Wong, AN Ananthakrishnan, ... Clinical Gastroenterology and Hepatology 21 (10), 2483-2495. e1, 2023 | 64 | 2023 |
| Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: a GETAID cohort M Uzzan, C Bresteau, D Laharie, C Stefanescu, C Bellanger, F Carbonnel, ... Alimentary Pharmacology & Therapeutics 54 (3), 312-319, 2021 | 56 | 2021 |
| Pregnancy in women with inflammatory bowel disease: a French nationwide study 2010‐2018 A Meyer, J Drouin, A Weill, F Carbonnel, R Dray‐Spira Alimentary Pharmacology & Therapeutics 52 (9), 1480-1490, 2020 | 51 | 2020 |
| Risk of inflammatory bowel disease in patients with psoriasis and psoriatic arthritis/ankylosing spondylitis initiating interleukin‐17 inhibitors: a nationwide population‐based … L Penso, C Bergqvist, A Meyer, P Herlemont, A Weill, M Zureik, ... Arthritis & Rheumatology 74 (2), 244-252, 2022 | 35 | 2022 |
| Risk of severe COVID‐19 in patients treated with IBD medications: a French nationwide study A Meyer, L Semenzato, M Zureik, A Weill, F Carbonnel, R Dray‐Spira Alimentary Pharmacology & Therapeutics 54 (2), 160-166, 2021 | 34 | 2021 |
| Colonoscopy in France during the COVID-19 pandemic A Meyer, J Drouin, M Zureik, A Weill, R Dray-Spira International journal of colorectal disease 36, 1073-1075, 2021 | 33 | 2021 |
| The effectiveness and safety of infliximab compared with biosimilar CT‐P13, in 3112 patients with ulcerative colitis A Meyer, J Rudant, J Drouin, J Coste, F Carbonnel, A Weill Alimentary Pharmacology & Therapeutics 50 (3), 269-277, 2019 | 33 | 2019 |
| Systematic review with meta‐analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti‐tumour necrosis factor L Parrot, C Dong, F Carbonnel, A Meyer Alimentary pharmacology & therapeutics 55 (4), 380-388, 2022 | 31 | 2022 |
| Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and/or anti‐TNF: a French nationwide study 2010–2018 A Meyer, J Drouin, A Weill, F Carbonnel, R Dray‐Spira Alimentary Pharmacology & Therapeutics 54 (3), 302-311, 2021 | 29 | 2021 |
| Long‐term outcome of patients with acute severe ulcerative colitis responding to intravenous steroids R Salameh, J Kirchgesner, M Allez, F Carbonnel, A Meyer, JM Gornet, ... Alimentary Pharmacology & Therapeutics 51 (11), 1096-1104, 2020 | 29 | 2020 |
| Vedolizumab clinical decision support tool predicts efficacy of vedolizumab but not ustekinumab in refractory Crohn’s disease H Alric, A Amiot, J Kirchgesner, X Tréton, M Allez, Y Bouhnik, L Beaugerie, ... Inflammatory Bowel Diseases 28 (2), 218-225, 2022 | 27 | 2022 |
| Drug use for gastrointestinal symptoms during pregnancy: a French nationwide study 2010–2018 A Meyer, M Fermaut, J Drouin, F Carbonnel, A Weill PloS one 16 (1), e0245854, 2021 | 26 | 2021 |
| Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: a GETAID multicentre cohort study M Fumery, A Defrance, X Roblin, R Altwegg, B Caron, X Hébuterne, ... Alimentary Pharmacology & Therapeutics 57 (4), 426-434, 2023 | 23 | 2023 |
| Serious infections in children born to mothers with inflammatory bowel disease with in utero exposure to thiopurines and anti-tumor necrosis factor A Meyer, M Taine, J Drouin, A Weill, F Carbonnel, R Dray-Spira Clinical Gastroenterology and Hepatology 20 (6), 1269-1281. e9, 2022 | 23 | 2022 |
| Food processing and risk of Crohn’s disease and ulcerative colitis: A European Prospective Cohort Study A Meyer, C Dong, C Casagrande, SSM Chan, I Huybrechts, G Nicolas, ... Clinical Gastroenterology and Hepatology 21 (6), 1607-1616. e6, 2023 | 21 | 2023 |
| Benefits and risks associated with continuation of anti–tumor necrosis factor after 24 weeks of pregnancy in women with inflammatory bowel disease: a nationwide emulation trial A Meyer, A Neumann, J Drouin, A Weill, F Carbonnel, R Dray-Spira Annals of Internal Medicine 175 (10), 1374-1382, 2022 | 21 | 2022 |
| Chronic pouchitis and Crohn's disease of the pouch after ileal pouch-anal anastomosis: Incidence and risk factors C Bresteau, A Amiot, J Kirchgesner, N De'Angelis, JH Lefevre, Y Bouhnik, ... Digestive and Liver Disease 53 (9), 1128-1135, 2021 | 20 | 2021 |
Alain WeillFrench National Health Insurance (Cnam). GIS EPI-PHARE ANSM-CNAMDirección de correo verificada de assurance-maladie.fr
